Related Experiment Video
Updated: May 8, 2026
11:22
Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing
Published on: October 15, 2019
Microbiota abnormalities in inflammatory airway diseases - Potential for therapy
Eva S Gollwitzer1, Benjamin J Marsland1
1Faculty of Biology and Medicine, University of Lausanne, Service de Pneumologie, CHUV, Lausanne, Switzerland.
Pharmacology & Therapeutics
|August 24, 2013
Summary
The gut microbiome influences health, and imbalances are linked to chronic diseases. Emerging research suggests the airway microbiome may also play a role in lung diseases, offering new therapeutic targets.
Area of Science:
- Microbiome research
- Pulmonary medicine
- Therapeutic strategies
Background:
- Intestinal microbiota dysbiosis is associated with chronic diseases like IBD, obesity, and asthma.
- A reduction in beneficial bacteria (e.g., Lactobacilli, Bifidobacteria) and an increase in pathogenic bacteria are often observed.
- The respiratory tract also possesses a distinct microbiota.
Purpose of the Study:
- To review advances in understanding the airway microbiota in chronic lung diseases.
- To discuss current and future strategies for manipulating the microbiota for disease prevention and treatment.
Main Methods:
- Literature review of studies on airway microbiota in chronic lung diseases.
- Analysis of findings on microbial composition differences between healthy and diseased lungs.
- Exploration of therapeutic approaches targeting the microbiota.
Main Results:
- The airway microbial composition differs between healthy lungs and those with chronic lung diseases (asthma, COPD, cystic fibrosis).
- Limited data currently exists on the direct contribution of airway microbiota to disease onset and progression.
- The airway microbiota is an emerging field with potential therapeutic implications.
Conclusions:
- The airway microbiota is a potential future therapeutic target, similar to the intestinal microbiota.
- Further research is needed to establish the direct role of airway microbiota in lung disease.
- Manipulation of the airway microbiota may offer novel treatment and prevention strategies for lung conditions.
Related Concept Videos
01:29Microbiota of the Respiratory Tract
The human respiratory tract, comprising the upper and lower segments, serves as a critical interface with the external environment. The upper respiratory tract (URT)—including the nostrils, sinuses, pharynx, and oropharynx—is heavily colonized by microbes, while the lower respiratory tract (LRT), composed of the larynx, trachea, bronchi, and lungs, was long thought to be sterile. However, recent molecular studies have revealed that the lungs are not devoid of microbes but act more like...
01:28Asthma I: Introduction
Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:20Asthma: Pathogenesis and Management
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...